Provided by Tiger Trade Technology Pte. Ltd.

Nuvation Bio, Inc.

6.07
+0.29005.02%
Post-market: 6.170.1000+1.65%19:30 EDT
Volume:5.74M
Turnover:34.88M
Market Cap:2.13B
PE:-13.84
High:6.16
Open:5.96
Low:5.92
Close:5.78
52wk High:9.75
52wk Low:2.99
Shares:351.12M
Float Shares:264.00M
Volume Ratio:0.89
T/O Rate:2.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4387
EPS(LYR):-0.6000
ROE:-47.81%
ROA:-12.36%
PB:8.40
PE(LYR):-10.12

Loading ...

Nuvation Bio schedules first-quarter financial results call and webcast

Reuters
·
Apr 21

Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

THOMSON REUTERS
·
Apr 21

A Look At Nuvation Bio’s Valuation As Ibtrozi Uptake And Q1 Earnings Expectations Gain Attention

Simply Wall St.
·
Apr 18

Nuvation Bio's Ibtrozi Gains Frontline Momentum Ahead of Key Q1 Print, Wedbush Says

MT Newswires Live
·
Apr 16

Nuvation Bio Price Target Maintained With a $11.00/Share by Wedbush

Dow Jones
·
Apr 16

Nuvation Bio (NUVB) Gets a Buy from Wedbush

TIPRANKS
·
Apr 16

Nuvation Bio announces annual shareholder meeting via webcast

Reuters
·
Apr 10

Nuvation Bio Chief Regulatory Officer Kerry Wentworth disposes 200,000 shares for $903,560

Reuters
·
Apr 09

RBC Capital Sticks to Their Buy Rating for Nuvation Bio (NUVB)

TIPRANKS
·
Apr 08

JonesTrading Sticks to Their Buy Rating for Nuvation Bio (NUVB)

TIPRANKS
·
Apr 07

RBC Raises Price Target on Nuvation Bio to $20 From $13, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Apr 06

Nuvation Bio Inc : RBC Raises Target Price to $20 From $13

THOMSON REUTERS
·
Apr 06

U.S. RESEARCH ROUNDUP-EQT, Las Vegas Sands, Twilio

Reuters
·
Apr 06

Is EMA Validation Of Taletrectinib Expanding Nuvation Bio’s (NUVB) Targeted Lung Cancer Opportunity?

Simply Wall St.
·
Apr 04

Nuvation Bio Price Target Maintained With a $11.00/Share by Wedbush

Dow Jones
·
Apr 02

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Apr 02

Sector Update: Health Care Stocks Advance Pre-Bell Wednesday

MT Newswires Live
·
Apr 01

Nuvation Bio acquires Japan rights to safusidenib from Daiichi Sankyo

Reuters
·
Apr 01

Nuvation Bio Inc - Buys Japan Rights to Safusidenib From Daiichi Sankyo

THOMSON REUTERS
·
Apr 01

Nuvation Bio Inc - Gains Ownership of Global Clinical Development Program for Safusidenib

THOMSON REUTERS
·
Apr 01